ID   PANC-1
AC   CVCL_0480
SY   Panc-1; PANC.1; Panc 1; PanC1; Panc1; PANC1; Panc-1-P
DR   BioGRID_ORCS_Cell_line; 190
DR   BCGO; BCGO_0000122
DR   BTO; BTO:0000304
DR   CLO; CLO_0008381
DR   CLO; CLO_0050102
DR   EFO; EFO_0002713
DR   MCCL; MCC:0000378
DR   CLDB; cl3872
DR   CLDB; cl3873
DR   CLDB; cl3874
DR   4DN; 4DNSRDQPS1VU
DR   AddexBio; C0018010/4923
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   ATCC; CRL-1469
DR   BCRC; 60284
DR   BCRJ; 0201
DR   BioSample; SAMN01821587
DR   BioSample; SAMN03472068
DR   BioSample; SAMN05292439
DR   BioSample; SAMN10987682
DR   cancercelllines; CVCL_0480
DR   CCRID; 1101HUM-PUMC000023
DR   CCRID; 3101HUMSCSP535
DR   CCRID; 3101HUMTCHu98
DR   CCRID; 4201HUM-CCTCC00309
DR   CCRID; 5301HUM-KCB08009YJ
DR   CCTCC; GDC0309
DR   Cell_Model_Passport; SIDM00610
DR   CGH-DB; 180-1
DR   CGH-DB; 9267-4
DR   ChEMBL-Cells; CHEMBL3307545
DR   ChEMBL-Targets; CHEMBL614139
DR   CLS; 300228
DR   Cosmic; 707250
DR   Cosmic; 710864
DR   Cosmic; 724643
DR   Cosmic; 730533
DR   Cosmic; 753625
DR   Cosmic; 808171
DR   Cosmic; 868242
DR   Cosmic; 873000
DR   Cosmic; 913307
DR   Cosmic; 918054
DR   Cosmic; 922248
DR   Cosmic; 923171
DR   Cosmic; 932521
DR   Cosmic; 947397
DR   Cosmic; 948377
DR   Cosmic; 949235
DR   Cosmic; 968106
DR   Cosmic; 1006367
DR   Cosmic; 1108335
DR   Cosmic; 1122348
DR   Cosmic; 1198204
DR   Cosmic; 1299304
DR   Cosmic; 1320459
DR   Cosmic; 1366282
DR   Cosmic; 1477432
DR   Cosmic; 1518236
DR   Cosmic; 1534320
DR   Cosmic; 1571781
DR   Cosmic; 1644316
DR   Cosmic; 1609544
DR   Cosmic; 1768264
DR   Cosmic; 2434107
DR   Cosmic; 2546060
DR   Cosmic; 2664043
DR   Cosmic; 2755953
DR   DepMap; ACH-000164
DR   DSMZ; ACC-783
DR   DSMZCellDive; ACC-783
DR   ECACC; 87092802
DR   EGA; EGAS00001000610
DR   ENCODE; ENCBS101NPD
DR   ENCODE; ENCBS314FVF
DR   ENCODE; ENCBS397PLZ
DR   ENCODE; ENCBS399ENC
DR   ENCODE; ENCBS425ENC
DR   ENCODE; ENCBS465AAA
DR   ENCODE; ENCBS466AAA
DR   ENCODE; ENCBS467AAA
DR   ENCODE; ENCBS470AAA
DR   ENCODE; ENCBS492WPY
DR   ENCODE; ENCBS556WYR
DR   ENCODE; ENCBS729QZR
DR   ENCODE; ENCBS761TKL
DR   ENCODE; ENCBS808TSD
DR   ENCODE; ENCBS830QHD
DR   ENCODE; ENCBS945URM
DR   GEO; GSM206532
DR   GEO; GSM244423
DR   GEO; GSM383934
DR   GEO; GSM472938
DR   GEO; GSM472939
DR   GEO; GSM621900
DR   GEO; GSM784698
DR   GEO; GSM887501
DR   GEO; GSM888583
DR   GEO; GSM923421
DR   GEO; GSM945246
DR   GEO; GSM945261
DR   GEO; GSM1024411
DR   GEO; GSM1022632
DR   GEO; GSM1374806
DR   GEO; GSM1374807
DR   GEO; GSM1374808
DR   GEO; GSM1435699
DR   GEO; GSM1435700
DR   GEO; GSM1435701
DR   GEO; GSM1588613
DR   GEO; GSM1588625
DR   GEO; GSM3333104
DR   GEO; GSM3333105
DR   GEO; GSM3333108
DR   GEO; GSM3333109
DR   IARC_TP53; 317
DR   IBRC; C10156
DR   IZSLER; BS TCL 49
DR   KCB; KCB 200788YJ
DR   KCB; KCB 200809YJ
DR   KCLB; 21469
DR   LiGeA; CCLE_087
DR   LINCS_LDP; LCL-1726
DR   Lonza; 818
DR   MetaboLights; MTBLS812
DR   NCBI_Iran; C556
DR   PharmacoDB; PANC1_1246_2019
DR   PRIDE; PXD002192
DR   PRIDE; PXD003198
DR   PRIDE; PXD032263
DR   Progenetix; CVCL_0480
DR   PubChem_Cell_line; CVCL_0480
DR   RCB; RCB2095
DR   SKY/M-FISH/CGH; 2001
DR   TKG; TKG 0606
DR   TOKU-E; 2865
DR   Ubigene; YC-C130
DR   Wikidata; Q54937550
RX   CelloPub=CLPUB00416;
RX   DOI=10.4172/jpb.1000057;
RX   PubMed=1140870;
RX   PubMed=1630814;
RX   PubMed=1764370;
RX   PubMed=6435863;
RX   PubMed=7809022;
RX   PubMed=7961102;
RX   PubMed=8026879;
RX   PubMed=8194712;
RX   PubMed=8286197;
RX   PubMed=9023415;
RX   PubMed=10027410;
RX   PubMed=11115575;
RX   PubMed=11169957;
RX   PubMed=11169959;
RX   PubMed=11787853;
RX   PubMed=12692724;
RX   PubMed=12800145;
RX   PubMed=14695172;
RX   PubMed=15126341;
RX   PubMed=15367885;
RX   PubMed=15688027;
RX   PubMed=15770730;
RX   PubMed=16912165;
RX   PubMed=18298655;
RX   PubMed=18380791;
RX   PubMed=18575732;
RX   PubMed=19077451;
RX   PubMed=20418756;
RX   PubMed=21515691;
RX   PubMed=21607521;
RX   PubMed=22460905;
RX   PubMed=22585861;
RX   PubMed=23325432;
RX   PubMed=25167228;
RX   PubMed=25394408;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=26216984;
RX   PubMed=26589293;
RX   PubMed=27067801;
RX   PubMed=27259358;
RX   PubMed=28196595;
RX   PubMed=30156359;
RX   PubMed=30894373;
RX   PubMed=31037374;
RX   PubMed=31068700;
RX   PubMed=31978347;
RX   PubMed=32058723;
RX   PubMed=32782605;
WW   https://en.wikipedia.org/wiki/PANC-1
WW   https://www.cellosaurus.org/pawefish/PancCellLineDescriptions/PANC-1.html
WW   http://dpsc.ccbr.utoronto.ca/cancer/get_cellline.pl?cellline=PANC-1
WW   https://www.synapse.org/#!Synapse:syn31544566
WW   http://genome.ucsc.edu/ENCODE/protocols/cell/human/PANC-1_Myers_protocol.pdf
WW   https://strap.nci.nih.gov/celline_detail.php?sample_id=65
WW   https://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/p/cell-lines-detail-179.html
WW   https://tcpaportal.org/mclp/
WW   https://www.phe-culturecollections.org.uk/media/120309/panc-1-cell-line-profile.pdf
CC   Part of: AKT genetic alteration cell panel (ATCC TCP-1029).
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: ENCODE project common cell types; tier 3.
CC   Part of: KuDOS 95 cell line panel.
CC   Part of: MD Anderson Cell Lines Project.
CC   Population: Caucasian.
CC   Doubling time: 21 +- 1.6 hours (PubMed=21515691); 25.83 +- 2.03 hours (PubMed=25394408); 25.8 +- 2.8 hours (PubMed=27067801); 52 hours (CLS=300228); ~42 hours (DSMZ=ACC-783); ~32 hours (PBCF); 15.02 hours (GrayJW panel).
CC   HLA typing: A*02:01,11:01; B*01,38; C*03,12 (PubMed=9023415).
CC   HLA typing: A*02,11; B*01,38; C*03,12 (PubMed=18575732).
CC   HLA typing: A*02:01,11:01; B*38:01,38:01; C*12:03,12:03; DQB1*06:07,06:07; DRB1*11:20,14:43 (PubMed=26589293).
CC   HLA typing: A*02:01:01,11:01:01; B*38:01:01; C*12:03:01; DPB1*12:01:02G,04:02:01G; DQA1*01:03:01; DQB1*06:03:01; DRB1*13:01:01 (CLS=300228).
CC   Karyotypic information: Has lost chromosome Y.
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=11787853; PubMed=15367885).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (PubMed=7809022; PubMed=7961102; PubMed=8026879; PubMed=11115575; PubMed=11787853; PubMed=15367885; PubMed=21607521; DepMap).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (PubMed=1630814; PubMed=1764370; PubMed=7961102; PubMed=8026879; PubMed=11115575; PubMed=11787853; PubMed=15367885; PubMed=21607521; DepMap).
CC   Omics: Array-based CGH.
CC   Omics: Deep exome analysis.
CC   Omics: Deep proteome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: H3K4me3 ChIP-seq epigenome analysis.
CC   Omics: Metabolome analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: Proteome analysis by 2D-DE/MS.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Omics: Transcriptome analysis by serial analysis of gene expression (SAGE).
CC   Genome ancestry: African=2.26%; Native American=0%; East Asian, North=2.09%; East Asian, South=0%; South Asian=0%; European, North=60%; European, South=35.65% (PubMed=30894373).
CC   Caution: Additional TP53 mutation in c.815T>C indicated incorrectly in PubMed=1630814.
CC   Derived from site: In situ; Pancreas; UBERON=UBERON_0001264.
ST   Source(s): AddexBio; ATCC; CCRID; CLS; DSMZ; ECACC; Genomics_Center_BCF_Technion; KCLB; PubMed=25877200; RCB; TKG
ST   Amelogenin: X
ST   CSF1PO: 10,12
ST   D10S1248: 14
ST   D12S391: 22
ST   D13S317: 11
ST   D16S539: 11
ST   D18S51: 12
ST   D19S433: 11,16
ST   D1S1656: 12,14
ST   D21S11: 28
ST   D22S1045: 16
ST   D2S1338: 23,24
ST   D2S441: 10,14
ST   D3S1358: 17
ST   D5S818: 11,13
ST   D6S1043: 11,12
ST   D7S820: 8,10
ST   D8S1179: 14,15
ST   FGA: 21
ST   Penta D: 14
ST   Penta E: 7,14
ST   TH01: 7,8
ST   TPOX: 8,11
ST   vWA: 15
DI   NCIt; C9120; Pancreatic ductal adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   56Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 46
//
RX   CelloPub=CLPUB00416;
RA   Oberlin L.;
RT   "Treatment of pancreatic carcinoma cell lines in vitro and vivo with a
RT   monoclonal antibody against the transferrin receptor.";
RL   Thesis VMD (2009), Justus-Liebig-Universitat Giessen, Germany.
//
RX   DOI=10.4172/jpb.1000057;
RA   Yamada M., Fujii K., Koyama K., Hirohashi S., Kondo T.;
RT   "The proteomic profile of pancreatic cancer cell lines corresponding
RT   to carcinogenesis and metastasis.";
RL   J. Proteomics Bioinformatics 2:1-18(2009).
//
RX   PubMed=1140870; DOI=10.1002/ijc.2910150505;
RA   Lieber M.M., Mazzetta J., Nelson-Rees W.A., Kaplan M., Todaro G.J.;
RT   "Establishment of a continuous tumor-cell line (PANC-1) from a human
RT   carcinoma of the exocrine pancreas.";
RL   Int. J. Cancer 15:741-747(1975).
//
RX   PubMed=1630814;
RA   Ruggeri B., Zhang S.-Y., Caamano J., DiRado M., Flynn S.D.,
RA   Klein-Szanto A.J.P.;
RT   "Human pancreatic carcinomas and cell lines reveal frequent and
RT   multiple alterations in the p53 and Rb-1 tumor-suppressor genes.";
RL   Oncogene 7:1503-1511(1992).
//
RX   PubMed=1764370; DOI=10.1038/bjc.1991.467;
RA   Barton C.M., Staddon S.L., Hughes C.M., Hall P.A., O'Sullivan C.,
RA   Kloppel G., Theis B., Russell R.C.G., Neoptolemos J., Williamson R.C.N.,
RA   Lane D.P., Lemoine N.R.;
RT   "Abnormalities of the p53 tumour suppressor gene in human pancreatic
RT   cancer.";
RL   Br. J. Cancer 64:1076-1082(1991).
//
RX   PubMed=6435863;
RA   Chang B.K., Black O. Jr., Gutman R.;
RT   "Inhibition of growth of human or hamster pancreatic cancer cell lines
RT   by alpha-difluoromethylornithine alone and combined with
RT   cis-diamminedichloroplatinum(II).";
RL   Cancer Res. 44:5100-5104(1984).
//
RX   PubMed=7809022; DOI=10.1097/00006676-199409000-00018;
RA   Sumi S., Beauchamp R.D., Townsend C.M. Jr., Pour P.M., Ishizuka J.,
RA   Thompson J.C.;
RT   "Lovastatin inhibits pancreatic cancer growth regardless of RAS
RT   mutation.";
RL   Pancreas 9:657-661(1994).
//
RX   PubMed=7961102; DOI=10.1111/j.1349-7006.1994.tb02898.x;
RA   Suwa H., Yoshimura T., Yamaguchi N., Kanehira K., Manabe T.,
RA   Imamura M., Hiai H., Fukumoto M.;
RT   "K-ras and p53 alterations in genomic DNA and transcripts of human
RT   pancreatic adenocarcinoma cell lines.";
RL   Jpn. J. Cancer Res. 85:1005-1014(1994).
//
RX   PubMed=8026879; DOI=10.1002/ijc.2910580207;
RA   Berrozpe G., Schaeffer J., Peinado M.A., Real F.X., Perucho M.;
RT   "Comparative analysis of mutations in the p53 and K-ras genes in
RT   pancreatic cancer.";
RL   Int. J. Cancer 58:185-191(1994).
//
RX   PubMed=8194712; DOI=10.1016/0016-5085(94)90422-7;
RA   Simon B., Weinel R., Hohne M., Watz J., Schmidt J., Kortner G.,
RA   Arnold R.;
RT   "Frequent alterations of the tumor suppressor genes p53 and DCC in
RT   human pancreatic carcinoma.";
RL   Gastroenterology 106:1645-1651(1994).
//
RX   PubMed=8286197; DOI=10.1038/bjc.1994.24;
RA   Lohr J.-M., Trautmann B., Gottler M., Peters S., Zauner I., Maillet B.,
RA   Kloppel G.;
RT   "Human ductal adenocarcinomas of the pancreas express extracellular
RT   matrix proteins.";
RL   Br. J. Cancer 69:144-151(1994).
//
RX   PubMed=9023415; DOI=10.1006/cimm.1996.1062;
RA   Seki N., Hoshino T., Kikuchi M., Hayashi A., Itoh K.;
RT   "HLA-A locus-restricted and tumor-specific CTLs in tumor-infiltrating
RT   lymphocytes of patients with non-small cell lung cancer.";
RL   Cell. Immunol. 175:101-110(1997).
//
RX   PubMed=10027410; DOI=10.1016/S0002-9440(10)65298-4;
RA   Ghadimi B.M., Schrock E., Walker R.L., Wangsa D., Jauho A.,
RA   Meltzer P.S., Ried T.;
RT   "Specific chromosomal aberrations and amplification of the AIB1
RT   nuclear receptor coactivator gene in pancreatic carcinomas.";
RL   Am. J. Pathol. 154:525-536(1999).
//
RX   PubMed=11115575; DOI=10.3892/or.8.1.89;
RA   Sun C.-L., Yamato T., Furukawa T., Ohnishi Y., Kijima H., Horii A.;
RT   "Characterization of the mutations of the K-ras, p53, p16, and SMAD4
RT   genes in 15 human pancreatic cancer cell lines.";
RL   Oncol. Rep. 8:89-92(2001).
//
RX   PubMed=11169957; DOI=10.1002/1097-0215(200002)9999:9999<::AID-IJC1014>3.0.CO;2-U;
RA   Wallrapp C., Hahnel S., Boeck W., Soder A., Mincheva A., Lichter P.,
RA   Leder G., Gansauge F., Sorio C., Scarpa A., Gress T.M.;
RT   "Loss of the Y chromosome is a frequent chromosomal imbalance in
RT   pancreatic cancer and allows differentiation to chronic
RT   pancreatitis.";
RL   Int. J. Cancer 91:340-344(2001).
//
RX   PubMed=11169959; DOI=10.1002/1097-0215(200002)9999:9999<::AID-IJC1049>3.0.CO;2-C;
RA   Sirivatanauksorn V., Sirivatanauksorn Y., Gorman P.A., Davidson J.M.,
RA   Sheer D., Moore P.S., Scarpa A., Edwards P.A.W., Lemoine N.R.;
RT   "Non-random chromosomal rearrangements in pancreatic cancer cell lines
RT   identified by spectral karyotyping.";
RL   Int. J. Cancer 91:350-358(2001).
//
RX   PubMed=11787853; DOI=10.1007/s004280100474;
RA   Moore P.S., Sipos B., Orlandini S., Sorio C., Real F.X., Lemoine N.R.,
RA   Gress T.M., Bassi C., Kloppel G., Kalthoff H., Ungefroren H.,
RA   Lohr J.-M., Scarpa A.;
RT   "Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras,
RT   p53, p16 and DPC4/Smad4.";
RL   Virchows Arch. 439:798-802(2001).
//
RX   PubMed=12692724; DOI=10.1007/s00428-003-0784-4;
RA   Sipos B., Moser S., Kalthoff H., Torok V., Lohr J.-M., Kloppel G.;
RT   "A comprehensive characterization of pancreatic ductal carcinoma cell
RT   lines: towards the establishment of an in vitro research platform.";
RL   Virchows Arch. 442:444-452(2003).
//
RX   PubMed=12800145; DOI=10.1002/gcc.10218;
RA   Adelaide J., Huang H.-E., Murati A., Alsop A.E., Orsetti B.,
RA   Mozziconacci M.-J., Popovici C., Ginestier C., Letessier A.,
RA   Basset C., Courtay-Cahen C., Jacquemier J., Theillet C., Birnbaum D.,
RA   Edwards P.A.W., Chaffanet M.;
RT   "A recurrent chromosome translocation breakpoint in breast and
RT   pancreatic cancer cell lines targets the neuregulin/NRG1 gene.";
RL   Genes Chromosomes Cancer 37:333-345(2003).
//
RX   PubMed=14695172;
RA   Iacobuzio-Donahue C.A., Ashfaq R., Maitra A., Adsay N.V.,
RA   Shen-Ong G.L., Berg K., Hollingsworth M.A., Cameron J.L., Yeo C.J.,
RA   Kern S.E., Goggins M.G., Hruban R.H.;
RT   "Highly expressed genes in pancreatic ductal adenocarcinomas: a
RT   comprehensive characterization and comparison of the transcription
RT   profiles obtained from three major technologies.";
RL   Cancer Res. 63:8614-8622(2003).
//
RX   PubMed=15126341; DOI=10.1158/0008-5472.CAN-03-3159;
RA   Heidenblad M., Schoenmakers E.F.P.M., Jonson T., Gorunova L.,
RA   Veltman J.A., van Kessel A.G., Hoglund M.;
RT   "Genome-wide array-based comparative genomic hybridization reveals
RT   multiple amplification targets and novel homozygous deletions in
RT   pancreatic carcinoma cell lines.";
RL   Cancer Res. 64:3052-3059(2004).
//
RX   PubMed=15367885; DOI=10.1097/00006676-200410000-00004;
RA   Loukopoulos P., Kanetaka K., Takamura M., Shibata T., Sakamoto M.,
RA   Hirohashi S.;
RT   "Orthotopic transplantation models of pancreatic adenocarcinoma
RT   derived from cell lines and primary tumors and displaying varying
RT   metastatic activity.";
RL   Pancreas 29:193-203(2004).
//
RX   PubMed=15688027; DOI=10.1038/sj.onc.1208383;
RA   Heidenblad M., Lindgren D., Veltman J.A., Jonson T., Mahlamaki E.H.,
RA   Gorunova L., van Kessel A.G., Schoenmakers E.F.P.M., Hoglund M.;
RT   "Microarray analyses reveal strong influence of DNA copy number
RT   alterations on the transcriptional patterns in pancreatic cancer:
RT   implications for the interpretation of genomic amplifications.";
RL   Oncogene 24:1794-1801(2005).
//
RX   PubMed=15770730; DOI=10.3748/wjg.v11.i10.1521;
RA   Ma J.-H., Patrut E., Schmidt J., Knaebel H.-P., Buchler M.W.,
RA   Marten A.;
RT   "Synergistic effects of interferon-alpha in combination with
RT   chemoradiation on human pancreatic adenocarcinoma.";
RL   World J. Gastroenterol. 11:1521-1528(2005).
//
RX   PubMed=16912165; DOI=10.1158/0008-5472.CAN-06-0721;
RA   Calhoun E.S., Hucl T., Gallmeier E., West K.M., Arking D.E.,
RA   Maitra A., Iacobuzio-Donahue C.A., Chakravarti A., Hruban R.H.,
RA   Kern S.E.;
RT   "Identifying allelic loss and homozygous deletions in pancreatic
RT   cancer without matched normals using high-density single-nucleotide
RT   polymorphism arrays.";
RL   Cancer Res. 66:7920-7928(2006).
//
RX   PubMed=18298655; DOI=10.1111/j.1582-4934.2008.00289.x;
RA   Pilarsky C., Ammerpohl O., Sipos B., Dahl E., Hartmann A.,
RA   Wellmann A., Braunschweig T., Lohr J.-M., Jesenofsky R., Friess H.,
RA   Wente M.N., Kristiansen G., Jahnke B., Denz A., Ruckert F.,
RA   Schackert H.K., Kloppel G., Kalthoff H., Saeger H.-D., Grutzmann R.;
RT   "Activation of Wnt signalling in stroma from pancreatic cancer
RT   identified by gene expression profiling.";
RL   J. Cell. Mol. Med. 12:2823-2835(2008).
//
RX   PubMed=18380791; DOI=10.1111/j.1349-7006.2008.00779.x;
RA   Suzuki A., Shibata T., Shimada Y., Murakami Y., Horii A.,
RA   Shiratori K., Hirohashi S., Inazawa J., Imoto I.;
RT   "Identification of SMURF1 as a possible target for 7q21.3-22.1
RT   amplification detected in a pancreatic cancer cell line by in-house
RT   array-based comparative genomic hybridization.";
RL   Cancer Sci. 99:986-994(2008).
//
RX   PubMed=18575732; DOI=10.3892/or.20.1.155;
RA   Kawaoka T., Oka M., Takashima M., Ueno T., Yamamoto K., Yahara N.,
RA   Yoshino S., Hazama S.;
RT   "Adoptive immunotherapy for pancreatic cancer: cytotoxic T lymphocytes
RT   stimulated by the MUC1-expressing human pancreatic cancer cell line
RT   YPK-1.";
RL   Oncol. Rep. 20:155-163(2008).
//
RX   PubMed=19077451; DOI=10.1159/000178871;
RA   Harada T., Chelala C., Crnogorac-Jurcevic T., Lemoine N.R.;
RT   "Genome-wide analysis of pancreatic cancer using microarray-based
RT   techniques.";
RL   Pancreatology 9:13-24(2009).
//
RX   PubMed=20418756; DOI=10.1097/MPA.0b013e3181c15963;
RA   Deer E.L., Gonzalez-Hernandez J., Coursen J.D., Shea J.E., Ngatia J.,
RA   Scaife C.L., Firpo M.A., Mulvihill S.J.;
RT   "Phenotype and genotype of pancreatic cancer cell lines.";
RL   Pancreas 39:425-435(2010).
//
RX   PubMed=21515691; DOI=10.1074/jbc.M111.226795;
RA   McCluskey J.T., Hamid M., Guo-Parke H., McClenaghan N.H., Gomis R.,
RA   Flatt P.R.;
RT   "Development and functional characterization of insulin-releasing
RT   human pancreatic beta cell lines produced by electrofusion.";
RL   J. Biol. Chem. 286:21982-21992(2011).
//
RX   PubMed=21607521; DOI=10.3892/or.1.6.1223;
RA   Iguchi H., Morita R., Yasuda D., Takayanagi R., Ikeda Y., Takada Y.,
RA   Shimazoe T., Nawata H., Kono A.;
RT   "Alterations of the p53 tumor-suppressor gene and ki-ras oncogene in
RT   human pancreatic cancer-derived cell-lines with different metastatic
RT   potential.";
RL   Oncol. Rep. 1:1223-1227(1994).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=22585861; DOI=10.1158/2159-8290.CD-11-0224;
RA   Marcotte R., Brown K.R., Suarez Saiz F.J., Sayad A., Karamboulas K.,
RA   Krzyzanowski P.M., Sircoulomb F., Medrano M., Fedyshyn Y., Koh J.L.Y.,
RA   van Dyk D., Fedyshyn B., Luhova M., Brito G.C., Vizeacoumar F.J.,
RA   Vizeacoumar F.S., Datti A., Kasimer D., Buzina A., Mero P.,
RA   Misquitta C., Normand J., Haider M., Ketela T., Wrana J.L.,
RA   Rottapel R., Neel B.G., Moffat J.;
RT   "Essential gene profiles in breast, pancreatic, and ovarian cancer
RT   cells.";
RL   Cancer Discov. 2:172-189(2012).
//
RX   PubMed=23325432; DOI=10.1101/gr.147942.112;
RA   Varley K.E., Gertz J., Bowling K.M., Parker S.L., Reddy T.E.,
RA   Pauli-Behn F., Cross M.K., Williams B.A., Stamatoyannopoulos J.A.,
RA   Crawford G.E., Absher D.M., Wold B.J., Myers R.M.;
RT   "Dynamic DNA methylation across diverse human cell lines and
RT   tissues.";
RL   Genome Res. 23:555-567(2013).
//
RX   PubMed=25167228; DOI=10.1038/bjc.2014.475;
RA   Hamidi H., Lu M., Chau K., Anderson L., Fejzo M.S., Ginther C.,
RA   Linnartz R., Zubel A., Slamon D.J., Finn R.S.;
RT   "KRAS mutational subtype and copy number predict in vitro response of
RT   human pancreatic cancer cell lines to MEK inhibition.";
RL   Br. J. Cancer 111:1788-1801(2014).
//
RX   PubMed=25394408; DOI=10.3892/or.2014.3599;
RA   Wang C.-F., Zhang W.-W., Fu M.-J., Yang A.-Q., Huang H.-H., Xie J.-M.;
RT   "Establishment of human pancreatic cancer gemcitabine-resistant cell
RT   line with ribonucleotide reductase overexpression.";
RL   Oncol. Rep. 33:383-390(2015).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=26216984; DOI=10.1073/pnas.1501605112;
RA   Daemen A., Peterson D., Sahu N., McCord R., Du X.-N., Liu B.,
RA   Kowanetz K., Hong R., Moffat J., Gao M., Boudreau A., Mroue R.,
RA   Corson L., O'Brien T., Qing J., Sampath D., Merchant M., Yauch R.L.,
RA   Manning G., Settleman J., Hatzivassiliou G., Evangelista M.;
RT   "Metabolite profiling stratifies pancreatic ductal adenocarcinomas
RT   into subtypes with distinct sensitivities to metabolic inhibitors.";
RL   Proc. Natl. Acad. Sci. U.S.A. 112:E4410-E4417(2015).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=27067801; DOI=10.1186/s12885-016-2297-y;
RA   Miura K., Kimura K., Amano R., Yamazoe S., Ohira G., Murata A.,
RA   Nishio K., Hasegawa T., Yashiro M., Nakata B., Ohira M., Hirakawa K.;
RT   "Establishment and characterization of new cell lines of anaplastic
RT   pancreatic cancer, which is a rare malignancy: OCUP-A1 and OCUP-A2.";
RL   BMC Cancer 16:268.1-268.13(2016).
//
RX   PubMed=27259358; DOI=10.1074/mcp.M116.058313;
RA   Humphrey E.S., Su S.-P., Nagrial A.M., Hochgrafe F., Pajic M.,
RA   Lehrbach G.M., Parton R.G., Yap A.S., Horvath L.G., Chang D.K.,
RA   Biankin A.V., Wu J.-M., Daly R.J.;
RT   "Resolution of novel pancreatic ductal adenocarcinoma subtypes by
RT   global phosphotyrosine profiling.";
RL   Mol. Cell. Proteomics 15:2671-2685(2016).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=30156359; DOI=10.1111/cas.13783;
RA   Sato T., Muramatsu T., Tanabe M., Inazawa J.;
RT   "Identification and characterization of TGFBI in circulating tumor
RT   cell subline from pancreatic cancer cell line.";
RL   Cancer Sci. 109:3623-3633(2018).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31037374; DOI=10.1007/s00216-019-01814-1;
RA   Lagies S., Schlimpert M., Braun L.M., Kather M., Plagge J., Erbes T.,
RA   Wittel U.A., Kammerer B.;
RT   "Unraveling altered RNA metabolism in pancreatic cancer cells by
RT   liquid-chromatography coupling to ion mobility mass spectrometry.";
RL   Anal. Bioanal. Chem. 411:6319-6328(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31978347; DOI=10.1016/j.cell.2019.12.023;
RA   Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III,
RA   Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K.,
RA   Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K.,
RA   Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A.,
RA   Sellers W.R., Gygi S.P.;
RT   "Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
RL   Cell 180:387-402.e16(2020).
//
RX   PubMed=32058723; DOI=10.1021/acs.jproteome.9b00840;
RA   Tan Z.-J., Zhu J.-H., Stemmer P.M., Sun L.-L., Yang Z.-C., Schultz K.,
RA   Gaffrey M.J., Cesnik A.J., Yi X.-P., Hao X.-H., Shortreed M.R.,
RA   Shi T.-J., Lubman D.M.;
RT   "Comprehensive detection of single amino acid variants and evaluation
RT   of their deleterious potential in a PANC-1 cell line.";
RL   J. Proteome Res. 19:1635-1646(2020).
//
RX   PubMed=32782605; DOI=10.3892/ol.2020.11825;
RA   Takagi K., Imura J., Shimomura A., Noguchi A., Minamisaka T.,
RA   Tanaka S., Nishida T., Hatta H., Nakajima T.;
RT   "Establishment of highly invasive pancreatic cancer cell lines and the
RT   expression of IL-32.";
RL   Oncol. Lett. 20:2888-2896(2020).
//